Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- THRX
- Price
- -
- Stock movement up
- +- (%)
- Company name
- Theseus Pharmaceuticals Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 181.28M
- Ent value
- 144.49M
- Price/Sales
- -
- Price/Book
- 0.81
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -67.02%
- 3 year return
- -
- 5 year return
- -
- 10 year return
- -
Last updated: 2024-12-17
DIVIDENDS
THRX does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 0.81 |
| EV to Sales | - |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 44.65M |
| EPS (TTM) | -1.28 |
| FCF per share (TTM) | -1.14 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | -488.37K |
| Operating income (TTM) | -66.52M |
| Net income (TTM) | -55.86M |
| EPS (TTM) | -1.28 |
| EPS (1y forward) | -1.07 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 46.89M |
| Net receivables | 0.00 |
| Total current assets | 209.59M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 4.45M |
| Total assets | 234.63M |
| Accounts payable | 1.31M |
| Short/Current long term debt | 3.66M |
| Total current liabilities | 7.00M |
| Total liabilities | 10.11M |
| Shareholder's equity | 224.52M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -49.63M |
| Capital expenditures (TTM) | 83.00K |
| Free cash flow (TTM) | -49.72M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -24.88% |
| Return on Assets | -23.81% |
| Return on Invested Capital | -24.80% |
| Cash Return on Invested Capital | -22.07% |
STOCK INFORMATION
Downside potential
Loading...
Downside potential data
| THRX | S&P500 | |
| Current price drop from All-time high | -79.79% | -1.42% |
| Highest price drop | -89.45% | -56.47% |
| Date of highest drop | 10 Nov 2023 | 9 Mar 2009 |
| Avg drop from high | -60.14% | -11.07% |
| Avg time to new high | 84 days | 12 days |
| Max time to new high | 560 days | 1805 days |
COMPANY DETAILS
Marketcap
181.28M
Marketcap category
Small-cap
Description
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors. The company also develops THE-349, a fourth-generation selective epidermal growth factor receptor inhibitor to address C797X-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts. As of February 14, 2024, Theseus Pharmaceuticals, Inc. operates as a subsidiary of Concentra Biosciences, LLC.
Employees
38
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner